News for hackers. Stuff that matters.

A comment on McKinsey Advised Johnson and Johnson on Increasing Opioid Sales. Parent comment

Re:McKinsey Advised Johnson and Johnson on Increasing Opioid... by ls612 on Thursday July 25, 2019 @04:16PM (#20529143)
The vast majority got their start in academic settings. Most of the R&D money (in particular the expensive phase 3 clinical trials) is spent by pharmaceutical companies.
[ Parent | on HN ]
Re:McKinsey Advised Johnson and Johnson on Increasing Opioid... by SolaceQuantum on Thursday July 25, 2019 @04:27PM (#20529287)
Yes, so the actual innovation occured in academic settings, as was the query.
[ Parent | on HN ]
Re:McKinsey Advised Johnson and Johnson on Increasing Opioid... by sgt101 on Thursday July 25, 2019 @05:01PM (#20529658)
No, that isn't the case. The fundamental research occurs in academia, but early development which includes working out how to deliver it, how to mitigate side-effects and then the clinical trials. Getting a drug into use is very distant from finding compounds in a lab.
[ Parent | on HN ]
Re:McKinsey Advised Johnson and Johnson on Increasing Opioid... by tathougies on Thursday July 25, 2019 @05:27PM (#20529932)
> so the actual innovation occured in academic settings, as was the query.

Well no not at all. Innovation is both the process itself + the supporting requirements necessary to make it work on a massive scale. We cannot minimize the cost of investment in making sure treatments are effective and non-harmfulu in the general population. That is a critical part of medical innovation.

[ Parent | on HN ]
Re:McKinsey Advised Johnson and Johnson on Increasing Opioid... by refurb on Thursday July 25, 2019 @10:23PM (#20531844)
Absolutely not.

That’s like saying Apple didn’t invent the iPhone because Shockley discovered transistors.

[ Parent | on HN ]